IGF-1 DES
Muscle Building, Performance
In short
- IGF-1 with the first three N-terminal amino acids removed (des(1-3)IGF-1).
- That truncation drops its affinity for IGF binding proteins by roughly two orders of magnitude, making it far more potent in tissue.
- Half-life is very short — around 20-30 minutes — the opposite trade-off from IGF-1 LR3.
- It occurs naturally in small amounts in human and bovine tissue; it is not purely synthetic.
- Same hypoglycaemia risk as the IGF-1 family, and the same proliferative questions.
Structure
A 67-amino-acid truncated IGF-1 variant. PubChem has no entry under this research-market name, and peptides and proteins of this size are represented by sequence rather than a small-molecule structure diagram.
How it works
Removing the N-terminal tripeptide from IGF-1 dramatically reduces binding protein affinity. Since binding proteins normally sequester the great majority of circulating IGF-1, this leaves far more free peptide available to act at the IGF-1 receptor — reported potency increases of roughly tenfold in some assays.
Signalling is identical to IGF-1: PI3K/Akt and MAPK activation driving protein synthesis, proliferation, and inhibition of apoptosis.
The contrast with IGF-1 LR3 matters. LR3 combines reduced binding protein affinity with an N-terminal extension that extends half-life to hours. DES has the reduced affinity without the extension, so it is potent but brief.
What the research shows
No human trial of IGF-1 DES has been conducted.
Mecasermin (recombinant IGF-1) is approved for severe primary IGF-1 deficiency and establishes what IGF-1 receptor signalling does clinically, along with hypoglycaemia as its dominant adverse effect.
Claims of localised muscle growth from site injection are unsupported by any human data.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — mecasermin (recombinant IGF-1), approved label | 40–120 µg/kg twice daily, with food | subcutaneous | FDA label |
| Animal — des(1-3)IGF-1 potency studies | Reported roughly 10x more potent than IGF-1 in tissue assays | — | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, peri-workout | 50–150 µg per site | subcutaneous or intramuscular |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The hypoglycaemia consideration is the immediate one: the approved IGF-1 product requires eating within 20 minutes of dosing. DES is more potent than IGF-1 at the receptor, which makes that requirement more pressing rather than less.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous or intramuscular injection is the community route, often peri-workout and near the trained muscle. The short half-life is the stated rationale for site injection, since the peptide does not persist long enough to distribute widely.
Food timing is not optional given the hypoglycaemia risk.
Side effects
Hypoglycaemia is the primary and immediate risk, through IGF-1 receptor and insulin receptor cross-reactivity. The mecasermin label carries this as its dominant adverse effect with mandatory food-timing instructions.
Other effects documented for recombinant IGF-1 include injection-site lipohypertrophy, tonsillar hypertrophy, and intracranial hypertension.
The long-term concern is proliferative: IGF-1 signalling inhibits apoptosis and drives proliferation, and higher circulating IGF-1 has been associated epidemiologically with several cancers.
Combinations
Combining with insulin is the specific dangerous pairing — the hypoglycaemia risk is additive and can be severe.
Combining with GH secretagogues raises endogenous IGF-1 alongside the exogenous analogue, compounding the same signal.
Research status
IGF-1 biology is extensively studied and mecasermin is approved. Des(1-3)IGF-1 has genuine biochemical characterisation, largely in the context of cell culture and livestock research where it was originally of interest.
No human clinical literature exists for it as administered.
Legal status
Not approved for human use in any jurisdiction. Sold as a laboratory reagent. Recombinant IGF-1 (mecasermin) is prescription-only where marketed.
WADA status
PROHIBITED AT ALL TIMES under WADA class S2 — growth hormone secretagogues, their releasing factors and mimetics are explicitly named. Any tested athlete should treat this as an anti-doping violation.
Conclusion
IGF-1 DES is the short-acting, high-potency member of the IGF-1 family, and it carries the family's acute risk in concentrated form.
Hypoglycaemia is the thing that will hurt you first and fastest. The proliferative question is real, unanswered, and slower.
Sources
Track your own IGF-1 DES protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.